Principles of Antibiotics Use & Spectrum of Some

Similar documents
Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

2015 Antibiotic Susceptibility Report

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

2016 Antibiotic Susceptibility Report

Antimicrobial Susceptibility Testing: Advanced Course

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

Advanced Practice Education Associates. Antibiotics

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing

Concise Antibiogram Toolkit Background

Approach to pediatric Antibiotics

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

European Committee on Antimicrobial Susceptibility Testing

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

EUCAST recommended strains for internal quality control

Aminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.

RCH antibiotic susceptibility data

CONTAGIOUS COMMENTS Department of Epidemiology

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Antimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

Antimicrobial susceptibility

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

European Committee on Antimicrobial Susceptibility Testing

Intrinsic, implied and default resistance

EDUCATIONAL COMMENTARY A PRIMER IN ANTIBIOTICS FOR THE LABORATORY PROFESSIONAL

Antibiotic Updates: Part II

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

Rational management of community acquired infections

21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review

Antimicrobial Agents 101. SWACM 2011 Christopher Doern, Ph.D., D(ABMM)

What s new in EUCAST methods?

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Other Beta - lactam Antibiotics

Antimicrobial Therapy

GENERAL NOTES: 2016 site of infection type of organism location of the patient

CONTAGIOUS COMMENTS Department of Epidemiology

ß-lactams. Sub-families. Penicillins. Cephalosporins. Monobactams. Carbapenems

Antibiotics 1. Lecture 8

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

Interactive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

CONTAGIOUS COMMENTS Department of Epidemiology

January 2014 Vol. 34 No. 1

Antimicrobial Susceptibility Patterns

Fundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3

Infectious Disease: Drug Resistance Pattern in New Mexico

Antimicrobial Susceptibility Testing: The Basics

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification

Pharmacology Week 6 ANTIMICROBIAL AGENTS

number Done by Corrected by Doctor

Appropriate antimicrobial therapy in HAP: What does this mean?

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

EAGAR Importance Rating and Summary of Antibiotic Uses in Humans in Australia

1. The preferred treatment option for an initial UTI episode in a 22-year-old female patient

Antibiotics (2): - Before you start: this lecture has a lot of names and things get entangled together, but I

Antimicrobials. Antimicrobials

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

Antimicrobials Agents Review

Mechanism of antibiotic resistance

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE

What s next in the antibiotic pipeline?

CF WELL Pharmacology: Microbiology & Antibiotics

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

Antibiotics. Antimicrobial Drugs. Alexander Fleming 10/18/2017

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Compliance of manufacturers of AST materials and devices with EUCAST guidelines

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

number Done by Corrected by Doctor

British Society for Antimicrobial Chemotherapy

Beta-lactam antibiotics - Cephalosporins

Antibiotic Updates: Part I

number Done by Corrected by Doctor Dr Hamed Al-Zoubi

Antimicrobial Resistance Trends in the Province of British Columbia

British Society for Antimicrobial Chemotherapy

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

January 2014 Vol. 34 No. 1

C&W Three-Year Cumulative Antibiogram January 2013 December 2015

Understanding the Hospital Antibiogram

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS

General Approach to Infectious Diseases

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

Introduction to Antimicrobials. Lecture Aim: To provide a brief introduction to antibiotics. Future lectures will go into more detail.

Transcription:

Principles of Antibiotics Use & Spectrum of Some Rabee Adwan. MD Infectious Diseases Consultant (Pediatric and Adult) Head Of ID Unit and IPAC Committee- AL-Makassed Hospital-AlQuds Head of IPAC Committee Istishri Arab Hospital-Ramallah 1 RABEE_ODWAN@YAHOO.COM

DISCLAIMERS There is No fun way to remember all Organisms and Antimicrobials :) The goal of this talk is to provide you with some basics and principles. 2

Some Principles 3

Start Smart! Always think on it as atriad:- Is it a Bacterial infection? HOST HOST: How sick is this person? Immunocompromised? Allergies? Ability to adhere to medications? comorbidities? pregnancy? Age? BUG: What organisms could be causing the problem? Does this patient have risk factors for resistant organisms? BUG DRUG DRUG: Will it penetrate to the organ involved? Do you need a bactericidal drug (eg. for endocarditis/cns infections)? Side effects? Renal or hepatic clearance? 4

ANTIBIOTIC CHOICE Don't guess about which antibiotic(s) to use - look it up or ask for help Don't delay giving antibiotics if the patient needs them (e.g., sepsis, meningitis) Don't forget to obtain appropriate cultures prior to starting antibiotics Reassess after 48-72 hours (or when culture results available) 5

USE BUNDLE:- THE 6 DS:- The Right Diagnosis The Right Drug The Right Dose The best Route of Delivery Attention To Deescalation The appropriate Duration of Rx 6

COMMON MISUSES OF ANTIBIOTICS 1. Prolonged Empiric Antimicrobial Treatment Without Clear Evidence of Infection. 2. Treatment of a Positive Clinical Culture in the Absence of Disease. 3. Failure to Narrow Antimicrobial Therapy When a Causative Organism Is Identified. 4. Prolonged Prophylactic Therapy. 5. Excessive Use of Certain Antimicrobial Agents. 7

8

1.Use antibiotics only when needed; teach the patient how to manage symptoms of nonbacterial infections; 2.Select the adequate ATB; precise targeting is better than shotgun therapy; 3.Consider pharmacokinetics and pharmacodynamics when selecting an ATB; use the shortest ATB course that has proven clinical efficacy; 4. Encourage patients compliance; 5.Use antibiotic combinations only in specific situations; 6.Avoid low quality and sub-standard drugs; prevent prescription changes at the drugstore; 7.Discourage self-prescription; 8.Follow only evidence-based guidelines; beware those sponsored by drug companies; 9.Rely (rationally) upon the clinical microbiology lab; and 10.Prescribe ATB empirically but intelligently; know local susceptibility trends, and also surveillance limitations. 9

KILLING ABILITY Bactericidal:- agents kill the Bacteria Bacteriostatic:-agents inhibit the growth of Bacteria 10

ANTIMICROBIAL PK/PD Concentration Dependant:- Rate and extent of Killing is dependent on the ratio that can be achieved between the peak drug concentration and the MIC of the infecting organism. Time Dependant:- Rate and extent of killing is dependant on the Duration of time that the drug is above the MIC of infecting organism.

BACTERIAL CLASSIFICATION: GRAM STAIN Gram +ve (blue/purple) Thick peptidoglycan cell wall retains primary stain Gram -ve (pink/red) Thin peptidoglycan cell wall does not retain primary stain 12

BACTERIA STRUCTURAL DIFFERENCES 13

14

Sulfonamides Trimethoprim Rifamycins Quinolones Metronidazole Aminoglycosides Tetracyclines (Tigecycline) Metabolism Transcription DNA Macrolides Clindamycin Chloramphenicol Synercid *Linezolid acts on the initiation complex Ribosomes 30 S 50 S mrna Colistin Daptomycin Glycopeptides B-Lactames Penecillins Carbapenems Monobactams Cephalosporins

Coverage Spectrum Of ATB

MOA of Action 17

Beta-lactams Members:- Penicillins Cephalosporins Carbapenems Monobactam MOA:- Cell wall synthesis inhibitors Antimicrobial Properties: Bactericidal Time dependant Killing

Penicillin G/V Narrow spectrum agent; mostly aerobic gram positive cocci Useful against: ß- hemolytic streptococci (Group A, B, C & G) Treponema pallidum (Syphillis) Gram negative spirochete N. menigitidis *note: resistance 1-3% oral anaerobes (peptococcus, peptostreptococcus) enteroccocus (E. facaelis, NOT E. faecium) NOT useful against: most gram negative organisms beta-lactamase producing organisms (S. aureus - ~90%)

Amoxicillin/Ampicillin narrow spectrum agent; mostly Gram positive aerobes, some Gram negative aerobes covers everything that penicillin does (streptococcus, enterococcus, oral anaerobes) Gram negative coverage (HiPEEL) - Non-beta-lactamase producing H. influenzae (~25% resistance) Proteus mirabilis E. coli (~30% resistance) Gram positive coverage better coverage of enterococcus (E.faecalis vs. penicillin) Listeria monocytogenes (HiPEEL) Useful against: ß- hemolytic streptococci (Group A, B, C & G), E. faecalis (<1% resistance), Listeria

Amoxicillin-Clavulanic Acid Amoxicillin + ß-lactamase inhibitor broad-spectrum agent extends spectrum of amoxicillin to cover more gram negatives (E.coli, H. influenzae, Salmonella, Shigella) + gut anaerobes (B. fragilis) Not useful against: Pseudomonas Like an oral pip/tazo (minus Pseudomonal coverage)

Piperacillin-Tazobactam Piperacillin + ß-lactamase inhibitor Most broad-spectrum penicillin; aerobic Gram positives (including MSSA, E. faecalis), difficult aerobic Gram negatives (including Enterobacter, Klebsiella, Serratia, Pseudomonas, Acinetobacter), anaerobes (including B. fragilis) Useful against: Pseudomonas, harder to kill Gram negatives (traditional ß-lactamase producers), most aerobic Gram positives (including MSSA) NOT useful against: MRSA, E. faecium

Cloxacillin Very narrow spectrum; gram positive aerobes drug of choice for MSSA maintains coverage for Streptococci (less so than penicillin/amoxicillin) some oral anaerobic coverage (less so than penicillin/amoxicillin) Not useful against: enterococci, N. meningitis Niche: methicillin-sensitive S. aureus

1st Generation Cephalosporins (cefazolin, cephalexin, cefadroxil) Narrow spectrum: aerobic gram positives (MSSA, ß-hemolytic Streptococcus) Some aerobic gram negatives (PEcK: Proteus, E.coli, Klebsiella) oral anaerobes Useful for: MSSA, ß-hemolytic Streptococcus Not useful for: Enterococci, gut anaerobes

2nd Generation Cephalosporins (cefuroxime, cefaclor, cefoxitin) Middle of the road coverage* Covers everything that 1st generations cover*: Gram positives: MSSA, Streptoccocus ( activity vs. 1st generation) Gram negatives: PEcK + H. influenzae & Moraxella oral anaerobes, NOT gut anaerobes* *exception: cefoxitin poor Gram positive coverage; covers B. fragilis (but resistance ~20%) Place in Therapy: oral stepdown for CAP

3rd Generation Cephalosporins (ceftriaxone, cefotaxime) Broad-spectrum Gram positive coverage: MSSA (reasonable coverage), Streptococcus (excellent coverage) Gram negatives: difficult to kill Gram negatives (Serratia, Enterobacter, Citrobacter), N.menigitidis, N.gonnorhea oral anaerobes NOT useful for: enterococcus, Pseudomonas, gut anaerboes

3rd Generation Cephalosporins (ceftazidime) Less broad-spectrum vs. ceftriaxone/cefotaxime Gram positive coverage: poor Gram negatives: difficult to kill Gram negatives (Serratia, Enterobacter, Citrobacter), Pseudomonas NOT useful for: enterococcus, gut anaerobes Useful for: treatment of documented Pseudomonal infections, empiric Gram negative coverage where Pseudomonal coverage is desired

3rd Generation Cephalosporins (cefixime) Gram positive coverage: poor Gram negatives: good; N. gonnorhea NOT useful for: enterococcus, gut anaerobes, Pseudomonas Useful for: treatment of N. gonnorhea (niche)

3rd Generation Cephalosporins (Cefdinir) Gram negative coverage: poor Gram Positive: good; NO staph aureus Coverage

4th Generation Cephalosporins (cefepime) broad-spectrum Like ceftriaxone, but: Gram positives: better activity vs. MSSA Gram negatives: Pseudomonas NOT useful for: enterococcus, gut anaerobes Useful for: treatment of documented Pseudomonal infections, empiric Gram negative coverage where Pseudomonal coverage is desired

CARBAPENEMS Ertapenem Meropenem Imipenem-cilastin Doripenem

CARBAPENEMS Tanks of the ß-lactams Extremely broad-spectrum: most aerobic Gram positives most aerobic Gram negatives- including ESBLs!!! most anaerobes Drugs of choice for ESBLs Reserve for serious infections with resistant organisms! :) NOT CRE

CARBAPENEMS (Ertapenem) Least broad-spectrum carbapenem Useful for: aerobic gram negatives (including ESBLs), aerobic gram positives (MSSA, Streptococcus), anaerobes Not useful for: enterococcus, Acinetobacter, Pseudomonas ( Pseudomonal sparing ), MRSA Doesn't Cross BBB

CARBAPENEMS (Meropenem, Imipenem, Doripenem) Most broad-spectrum of all the carbapenems like ertapenem, but also cover: Pseudomonas aeruginosa Enterococcus Acinetobacter Generally all 3 agents considered clinically equivalent, but based on MIC data: E.faecalis (I > M = D) Pseudomonas (D > M > I) Acinetobacter ( I > M = D) Bottom line: basically cover everything, except for MRSA, VRE

Vancomycin Bactericidal Time-dependent killing Inhibits cell wall formation Narrow spectrum - ONLY Gram positives: Aerobes: Staphylococci (MRSA, MSSA, CNST), Enterococci (E. faecalis & E. faecium) Anaerobes: C. difficile, Propionibacterium spp. Useful for: gram positive infections (MRSA, E. faecium) Not useful for: any gram negative, VRE

Fluoroquinolones Members Gram Negative Ciprofloxacin Levofloxacin Moxifloxacin Gram Positive Gemifloxacin Antimicrobial Properties bactericidal concentration-dependent killing Mechanism of Action: inhibit DNA gyrase/topoisomerase inhibit DNA replication

Fluoroquinolones (Ciprofloxacin) Relatively narrow spectrum mostly aerobic gram negatives (including Pseudomonas) unreliable gram positive coverage unreliable anaerobic coverage (gut & oral) Useful for: aerobic gram negatives (Pseudomonas if susceptible) Not useful for: gram positive or anaerobic infections

Fluoroquinolones (levofloxacin, moxifloxacin, Gemifloxacin) Respiratory fluoroquinolones (cover S. pneumoniae) Broad-spectrum aerobic gram positives (excellent S. pneumoniae coverage, reasonable MSSA coverage) aerobic gram negatives atypicals (Chlamydia, Mycoplasma, Legionella) Differences between agents: Gram negatives: L > M (moxifloxacin has inferior Gram neg. coverage) Pseudomonas: levofloxocin (note increasing resistance ~30%), NOT moxifloxacin or Gemi gut anaerobes: moxifloxacin (note: increasing resistance ~30%) NOT levofloxacin or Gemi Useful for: aerobic gram positives/gram negatives, atypicals (classic indication: CAP) Not useful for: MRSA, enterococcus

Metronidazole (Flagyl) Bactericidal with Concentration-dependent activity Free radical formation ( DNA damage) Narrow spectrum: anaerobes only Highly active against: gut anaerobes (B. fragilis, Clostridium spp) Variably active against: Peptostreptococcus (oral anaerobe) Inactive against: E. corrodens (human bite pathogen), Actinomyces (oral anaerobe), Propionibacterium spp. Other: Trichomonas spp., Giardia spp. Useful for: intra-abdominal anaerobic infections, C. difficile infections

Cotrimoxazole (Trimethoprim/Sulfamethoxazole) Bactericidal with Time-dependent activity Inhibits folate synthesis Broad-spectrum variable activity against MRSA/ MSSA) & streptococci! (check C&S before using) most aerobic gram negatives, ESBLS, NOT Pseudomonas others: Pneumocystis, Burkholderia cepacia (GNB), Stenotrophomonas maltophilia (GNB), Nocardia (GPB) Niches: MRSA (check C&S), ESBLs, Pneumocystis, Burkholderia cepacia, Stenotrophomonas maltophilia, Nocardia If have a highly resistant organism, consider It!

Aminoglycosides Members Tobramycin Gentamicin Amikacin Antimicrobial Properties bactericidal concentration-dependent killing Mechanism of Action: inhibit protein synthesis

Aminoglycosides Narrow spectrum; aerobic gram negatives only (including ESBLs) Can be used for synergy with a ß-lactam against Gram positives (streptococci, enterococci) Differences between agents: Klebsiella, Serratia: G > T > A Pseudomonas: T > G >A Amikacin has lowest resistance; but 4X higher MICs Useful for: aerobic gram negatives, ESBLs, Pseudomonas (Tobramycin) Not useful for: gram positives (except synergy with ß-lactams)

Clindamycin Bacteriostatic Time-dependent activity Inhibit protein synthesis Narrow spectrum: Gram positives & anaerobes Gram positive aerobes: Staphylococcus (MSSA, CA-MRSA note increasing resistance ~30%), Streptococcus (note increasing resistance) anaerobes: gut anaerobes (B. fragilis, Clostridium spp), oral anaerobes Useful for: MSSA/MRSA(check C&S), oral anaerobes Not useful for: any aerobic gram negative, enterococcus Caution: gut anaerobes, Staphylococcus

Macrolides Members Erythromycin Azithromycin Clarithromycin Antimicrobial Properties bacteriostatic Time-dependent killing Mechanism of Action: inhibit 50S ribosomal unit inhibit protein synthesis

Macrolides Relatively broad-spectrum Gram positives: Streptococci (note increasing resistance with S. pneumoniae ~20%) some Gram negatives (A & C only): H. influenzae, M. cattarhalis atypicals NO anaerobic coverage Niche: RTIs, Legionella Not useful for: MRSA, enterococcus

Tetracyclines Members Tetracycline Doxycycline Minocycline Antimicrobial Properties bacteriostatic time-dependent killing Mechanism of Action: inhibit protein synthesis

Tetracyclines broad-spectrum Aerobic Gram positives: Streptococci, Staphylococci (including MRSA!), Listeria Aerobic Gram negatives: easy to kill (E.coli, Klebsiella), N. menigtidis, Brucella spp. Atypicals Others: P. acnes, Vibrio, Treponema pallidum, H. pyelori, Plaspmodium spp. (malaria), Bartonella, spp., Rickettsiae Niches: MRSA, atypicals, Rickettsiae, Bartonella If have a highly resistant organism, consider a tetracycline!

Linezolid (Zyvox) Bacteriostatic Time-dependent activity Inhibition of protein synthesis Spectrum: narrow - aerobic Gram positives Staphylococci (MSSA, MRSA, CNST) Streptococci (penicillin-resistant) Enterococci (E. faecalis, E. faecium, VRE) Useful for: resistant aerobic Gram positives Not useful for: any gram negative, any anaerobe

Daptomycin Bactericidal Concentration-dependent Disruption of the bacterial cell membrane Narrow spectrum aerobic Gram positives Staphylococci (MSSA, MRSA, CNST) Streptococci (penicillin-resistant) Enterococci (E. faecalis, E. faecium, VRE) Useful for: resistant aerobic Gram positives Not useful for: any gram negative, any anaerobe, Chest infection!

Tigecycline (Tygacil) Bactericidal Time- dependent activity Inhibit inhibit protein synthesis Special member of the Tetracycline family VERY broad-spectrum: aerobic Gram positives: MSSA/MRSA, Streptococci, Enterococci (-faecalis, -faecium, VRE) most gram negatives, ESBLS, CREs (NOT 3Ps: Pseudomonas, Providencia, Proteus & Morganella) anaerobes: mostly oral (poor activity vs. B. fragilis) Useful for: most aerobic Gram positives & negatives, including resistants (MRSA, VRE, ESBLs) Not useful for: Pseudomonas, Proteus, Morganella, Providencia, gut anaerobes

Polymixin E (Colistin) 1962 Bactericidal Concentration-dependent Disruption of the bacterial outer membrane Narrow spectrum: aerobic Gram negatives Reliable activity against: ESBLs, CREs, Pseudomonas, Acinetobacter Less reliable against: Serratia spp, Proteus, spp, Providencia spp. B. Cepatia Useful for: highly resistant aerobic gram negative infections where there are no other options Not useful for: Gram positives

Miscellaneous

Fosfomycin Act on Cell wall synthesis Available as PO option Niche: indicated for the treatment of cystitis only (NOT pyelonephritis, abscess) caused by: E.coli (including ESBLs) E. faecalis

Nitrofurantoin Relatively broad-spectrum: aerobic gram negatives: E.coli, Klebsiella, ESBLs Use for Cystitis & prophylaxis (NOT: Proteus, Serratia, Pseudomonas) aerobic Gram positives: Enterococci (-faecalis, -faecium, VRE) Niche drug: urinary tract (cystitis ONLY) useful for ESBL cystitis Caution: insufficient serum levels to treat pyelonephritis (+/- bacteremia) 55

Take home Messages Antibiotics use is the single most important factor leading to antibiotic resistance. Up to 50% of all antibiotics prescribed are not needed. What to do? Promote appropriate antibiotics use (ASP). Start Smart and then go with 6 Ds Bundle! 56